Adaptimmune Therapeutics Plc - ADR

-0.03 (-1.72%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)276.80M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.57 Million
Adjusted EPS-$0.29
See more estimates
10-Day MA$1.69
50-Day MA$1.64
200-Day MA$3.15
See more pivots

Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX
United Kingdom
Phone: +44.1235.430000
Number of Employees: 494


Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.